CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top winning strategies

3.2.1.1. Top winning strategies, by year, 2015-2018*
3.2.1.2. Top winning strategies, by development, 2015-2018* (%)
3.2.1.3. Top winning strategies, by company, 2015-2018*

3.2.2. Top investment pockets

3.3. Market share analysis, 2016
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rapidly aging population
3.4.1.2. High incidence of neurodegenerative disorders
3.4.1.3. Benefits of smart drugs

3.4.2. Restraints

3.4.2.1. Ethical issues

3.4.3. Opportunities

3.4.3.1. Effective strength of the drugs

CHAPTER 4: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Aricept

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Exelon

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Namenda

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Razadyne

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Provigil

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Ritalin

4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Adderall

4.8.1. Key market trends, growth factors and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

4.9. Others

4.9.1. Key market trends, growth factors and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country

CHAPTER 5: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Disease treatment

5.2.1. Market size and forecast by type
5.2.2. Developmental conditions

5.2.2.1. Market size and forecast

5.2.3. Neurodegenerative disorders

5.2.3.1. Market size and forecast

5.2.4. Market size and forecast, by region
5.2.5. Market analysis, by country

5.3. Academic performance

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Athletic performance

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. Others

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

CHAPTER 6: COGNITIVE AND MEMORY ENHANCER DRUGS MARKET BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors and opportunities
6.2.2. North America market size and forecast, by country

6.2.2.1. U.S. cognitive and memory enhancer drugs market

6.2.2.1.1. U.S. market size and forecast, by product
6.2.2.1.2. U.S. market size and forecast, by application

6.2.2.2. Canada cognitive and memory enhancer drugs market

6.2.2.2.1. Canada market size and forecast, by product
6.2.2.2.2. Canada market size and forecast, by application

6.2.2.3. Mexico cognitive and memory enhancer drugs market

6.2.2.3.1. Mexico market size and forecast, by product
6.2.2.3.2. Mexico market size and forecast, by application

6.2.3. North America market size and forecast, by product
6.2.4. North America market size and forecast, by application

6.3. Europe

6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by country

6.3.2.1. Germany cognitive and memory enhancer drugs market

6.3.2.1.1. Germany market size and forecast, by product
6.3.2.1.2. Germany market size and forecast, by application

6.3.2.2. France cognitive and memory enhancer drugs market

6.3.2.2.1. France market size and forecast, by product
6.3.2.2.2. France market size and forecast, by application

6.3.2.3. UK cognitive and memory enhancer drugs market

6.3.2.3.1. UK market size and forecast, by product
6.3.2.3.2. UK market size and forecast, by application

6.3.2.4. Italy cognitive and memory enhancer drugs market

6.3.2.4.1. Italy market size and forecast, by product
6.3.2.4.2. Italy market size and forecast, by application

6.3.2.5. Spain cognitive and memory enhancer drugs market

6.3.2.5.1. Spain market size and forecast, by product
6.3.2.5.2. Spain market size and forecast, by application

6.3.2.6. Rest of Europe cognitive and memory enhancer drugs market

6.3.2.6.1. Rest of Europe market size and forecast, by product
6.3.2.6.2. Rest of Europe market size and forecast, by application

6.3.3. Europe market size and forecast, by product
6.3.4. Europe market size and forecast, by application

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by country

6.4.2.1. Japan cognitive and memory enhancer drugs market

6.4.2.1.1. Japan market size and forecast, by product
6.4.2.1.2. Japan market size and forecast, by application

6.4.2.2. China cognitive and memory enhancer drugs market

6.4.2.2.1. China market size and forecast, by product
6.4.2.2.2. China market size and forecast, by application

6.4.2.3. India cognitive and memory enhancer drugs market

6.4.2.3.1. India market size and forecast, by product
6.4.2.3.2. India market size and forecast, by application

6.4.2.4. Australia cognitive and memory enhancer drugs market

6.4.2.4.1. Australia market size and forecast, by product
6.4.2.4.2. Australia market size and forecast, by application

6.4.2.5. Rest of Asia-Pacific cognitive and memory enhancer drugs market

6.4.2.5.1. Rest of Asia-Pacific market size and forecast, by product
6.4.2.5.2. Rest of Asia-Pacific market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by product
6.4.4. Asia-Pacific market size and forecast, by application

6.5. LAMEA

6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast by country

6.5.2.1. Brazil cognitive and memory enhancer drugs market

6.5.2.1.1. Brazil market size and forecast, by product
6.5.2.1.2. Brazil market size and forecast, by application

6.5.2.2. Saudi Arabia cognitive and memory enhancer drugs market

6.5.2.2.1. Saudi Arabia market size and forecast, by product
6.5.2.2.2. Saudi Arabia market size and forecast, by application

6.5.2.3. South Africa cognitive and memory enhancer drugs market

6.5.2.3.1. South Africa market size and forecast, by product
6.5.2.3.2. South Africa market size and forecast, by application

6.5.2.4. Rest of LAMEA cognitive and memory enhancer drugs market

6.5.2.4.1. Rest of LAMEA market size and forecast, by product
6.5.2.4.2. Rest of LAMEA market size and forecast, by application

6.5.3. LAMEA market size and forecast, by product
6.5.4. LAMEA market size and forecast, by application

CHAPTER 7: COMPANY PROFILES

7.1. Allergan Plc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. AlternaScript LLC

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio

7.3. Ceretropic

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio

7.4. Eisai Co. Ltd.

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. Johnson & Johnson

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. Novartis International AG

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. Pfizer Inc.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. Shire Plc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Takeda Pharmaceutical Company Ltd.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance